TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07027345: A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Sponsor: BioMendics, LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,120,800

Rescue Site Savings

+$2,058,400

Unlock Full NCT07027345 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07027345 Rescue Dossier →